Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge

作者：Michael K. Lo, Friederike Feldmann, Joy Gary, Robert Jordan, Roy Bannister, Jacqueline Cronin, Nishi Patel, John D. Klena, Stuart T. Nichol, Tomáš Cihlář, Sherif R. Zaki, Heinz Feldmann, Christina F. Spiropoulou, Emmie de Wit · 发表于：Science Translational Medicine · 年份：2019 · DOI：10.1126/scitranslmed.aau9242 · 被引用次数：279 · 研究领域：Virology and Viral Diseases、Viral Infections and Vectors、Animal Disease Management and Epidemiology

spp. fruit bats, to humans, it causes respiratory and neurological disease with a case-fatality rate about 70%. Human-to-human transmission has been observed during Nipah virus outbreaks in Bangladesh and India. A therapeutic treatment for Nipah virus disease is urgently needed. Here, we tested the efficacy of remdesivir (GS-5734), a broad-acting antiviral nucleotide prodrug, against Nipah virus Bangladesh genotype in African green monkeys. Animals were inoculated with a lethal dose of Nipah virus, and a once-daily intravenous remdesivir treatment was initiated 24 hours later and continued for 12 days. Mild respiratory signs were observed in two of four treated animals, whereas all control animals developed severe respiratory disease signs. In contrast to control animals, which all succumbed to the infection, all remsdesivir-treated animals survived the lethal challenge, indicating that remdesivir represents a promising antiviral treatment for Nipah virus infection.